Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. May 10, 2014; 3(2): 54-60
Published online May 10, 2014. doi: 10.5317/wjog.v3.i2.54
Published online May 10, 2014. doi: 10.5317/wjog.v3.i2.54
Chemotherapy for gynaecological malignancies and fertility preservation
Joseph J Sacco, Joanne Cliff, John A Green, Department of Medical Oncology, Clatterbridge Cancer Centre, Bebington, Wirral CH63 4JY, United Kingdom
Author contributions: All authors performed a literature search, wrote and reviewed the manuscript.
Correspondence to: Dr. John A Green, Department of Medical Oncology, Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Wirral CH63 4JY, United Kingdom. j.a.green@liverpool.ac.uk
Telephone: +44-151-4827793 Fax: +44-151-4827675
Received: February 28, 2013
Revised: May 31, 2013
Accepted: August 4, 2013
Published online: May 10, 2014
Processing time: 438 Days and 1.9 Hours
Revised: May 31, 2013
Accepted: August 4, 2013
Published online: May 10, 2014
Processing time: 438 Days and 1.9 Hours
Core Tip
Core tip: This paper summarises the main scenarios in which infertility presents a clinical problem in gynaecological malignancies subsequent to the use of chemotherapy. Many patients may have pre-existing infertility due to related medical conditions, and prior surgical interventions may be an important factor. Other factors to be considered include the associated prognosis and the potential need for rapid commencement of chemotherapy. The various technologies for fertility preservation are reviewed and their strengths and weaknesses discussed. The paper stresses that an individualised approach is necessary for each patient and that discussion of the issues at an early stage of management is important.